Arsenic methylation capability, heme oxygenase-1 and NADPH quinone oxidoreductase-1 genetic polymorphisms and the stage and grade of urothelial carcinomas

Urologia Internationalis

Volumn 80, Issue 4, 2008, Pages 405-412

  Huang, Steven K ^a,b   Chiu, Allen Wen Hsiang ^b,c   Pu, Yeong Shiau ^d   Huang, Yung Kai ^a   Chung, Chi Jung ^e   Tsai, Hui Ju ^f   Yang, Mo Hsiung ^g   Chen, Chien Jen ^h,i   Hsueh, Yu Mei ^f  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b CHI MEI MEDICAL CENTER   (Taiwan)

^c TAIPEI CITY HOSPITAL   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^e TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^f TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^g NATIONAL TSING HUA UNIVERSITY   (Taiwan)

^h GENOMICS RESEARCH CENTER   (Taiwan)

ⁱ NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Arsenic; Bladder neoplasms; Methylation

Indexed keywords

ARSENIC; CACODYLIC ACID; METHANEARSONIC ACID;

ADULT; AGED; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; BLADDER CARCINOMA; CANCER GRADING; CANCER STAGING; DNA METHYLATION; FEMALE; GENE; GENETIC POLYMORPHISM; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HO 1 GENE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NQO1 GENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TAIWAN; URINALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ARSENIC; ARSENIC POISONING; CARCINOMA, TRANSITIONAL CELL; COHORT STUDIES; DNA METHYLATION; ENVIRONMENTAL EXPOSURE; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NADH, NADPH OXIDOREDUCTASES; NEOPLASM STAGING; POLYMORPHISM, GENETIC; PROBABILITY; PROGNOSIS; RISK ASSESSMENT; SURVIVAL ANALYSIS; TAIWAN; URINARY BLADDER NEOPLASMS;

EID: 46249134014     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000132699     Document Type: Article

References (51)

1. Department of Health ROC: Cancer Registry Annual Report Republic of China, 1999; in Department of Health ROC (ed): Taipei, Department of Health, Executive, Yuan 1998, 2002.
2. Chou YH, Huang CH: Unusual clinical presentation of upper urothelial carcinoma in Taiwan. Cancer 1999;85:1342-1344.
3. Chen CJ, Kuo TL, Wu MM: Arsenic and cancers. Lancet 1988;i:414-415.
4. Chiou HY, Chiou ST, Hsu YH, Chou YL, Tseng CH, Wei ML, Chen CJ: Incidence of transitional cell carcinoma and arsenic in drinking water: a follow-up study of 8,102 residents in an arseniasis-endemic area in northeastern Taiwan. Am J Epidemiol 2001;153:411-418.
5. Lee SH, Lin JS, Tzai TS, Chow NH, Tong YC, Yang WH, Chang CC, Cheng HL: Prognostic factors of primary transitional cell carcinoma of the upper urinary tract. Eur Urol 1996;29:266-270.
6. Yang MH, Chen KK, Yen CC, Wang WS, Chang YH, Huang WJ, Fan FS, Chiou TJ, Liu JH, Chen PM: Unusually high incidence of upper urinary tract urothelial carcinoma in Taiwan. Urology 2002;59:681-687.
7. Lee SE, Park MS: Prognostic factors for survival in patients with transitional cell carcinoma of the bladder: evaluation by histopathologic grade, pathologic stage and flow-cytometric analysis. Eur Urol 1996;29:193-198.
8. Zieger K, Wolf H, Olsen PR, Hojgaard K: Long-term survival of patients with bladder tumours: the significance of risk factors. Br J Urol 1998;82:667-672.
9. Andreae MO: Determination of arsenic species in natural waters. Anal Chem 1977;49:820-823.
10. Vahter M, Marafante E, Dencker L: Tissue distribution and retention of 74As-dimethylarsinic acid in mice and rats. Arch Environ Contam Toxicol 1984;13:259-264.
11. Hsueh YM, Chiou HY, Huang YL, Wu WL, Huang CC, Yang MH, Lue LC, Chen GS, Chen CJ: Serum beta-carotene level, arsenic methylation capability, and incidence of skin cancer. Cancer Epidemiol Biomarkers Prev 1997;6:589-596.
12. Chen YC, Su HJ, Guo YL, Hsueh YM, Smith TJ, Ryan LM, Lee MS, Christiani DC: Arsenic methylation and bladder cancer risk in Taiwan. Cancer Causes Control 2003;14:303-310.
13. Lind C, Cadenas E, Hochstein P, Ernster L: DT-diaphorase: purification, properties, and function. Methods Enzymol 1990;186:287-301.
14. Cadenas E: Antioxidant and prooxidant functions of DT-diaphorase in quinone metabolism. Biochem Pharmacol 1995;49:127-140.
15. Jaiswal AK, McBride OW, Adesnik M, Nebert DW: Human dioxin-inducible cytosolic NAD(P)H:menadione oxidoreductase: cDNA sequence and localization of gene to chromosome 16. J Biol Chem 1988;263:13572-13578.
16. Lafuente MJ, Casterad X, Trias M, Ascaso C, Molina R, Ballesta A, Zheng S, Wiencke JK, Lafuente A: NAD(P)H:quinone oxidoreductase-dependent risk for colorectal cancer and its association with the presence of K-ras mutations in tumors. Carcinogenesis 2000;21:1813-1819.
17. Lin P, Hsueh YM, Ko JL, Liang YF, Tsai KJ, Chen CY: Analysis of NQO1, GSTP1, and MnSOD genetic polymorphisms on lung cancer risk in Taiwan. Lung Cancer 2003;40:123-129.
18. Park SJ, Zhao H, Spitz MR, Grossman HB, Wu X: An association between NQO1 genetic polymorphism and risk of bladder cancer. Mutat Res 2003;536:131-137.
19. Maines MD: Heme oxygenase: function, multiplicity, regulatory mechanisms, and clinical applications. FASEB J 1988;2:2557-2568.
20. Abraham NG, Drummond GS, Lutton JD, Kappas A: The biological significance and physiological role of heme oxygenase. Cell Physiol Biochem 1996;6:129-168.
21. Maines MD: Heme oxygenase: function, multiplicity, regulatory mechanisms, and clinical applications. FASEB J 1988;2:2557-2568.
22. Kutty RK, Kutty G, Rodriguez IR, Chader GJ, Wiggert B: Chromosomal localization of the human heme oxygenase genes: heme oxygenase-1 (HMOX1) maps to chromosome 22q12 and heme oxygenase-2 (HMOX2) maps to chromosome 16p13.3. Genomics 1994;20:513-516.
23. Yamada N, Yamaya M, Okinaga S, Nakayama K, Sekizawa K, Shibahara S, Sasaki H: Microsatellite polymorphism in the heme oxygenase-1 gene promoter is associated with susceptibility to emphysema. Am J Hum Genet 2000;66:187-195.
24. Chen YC, Amarasiriwardena CJ, Hsueh YM, Christiani DC: Stability of arsenic species and insoluble arsenic in human urine. Cancer Epidemiol Biomarkers Prev 2002;11:1427-1433.
25. Hsueh YM, Huang YL, Huang CC, Wu WL, Chen HM, Yang MH, Lue LC, Chen CJ: Urinary levels of inorganic and organic arsenic metabolites among residents in an arseniasis-hyperendemic area in Taiwan. J Toxicol Environ Health [A] 1998;54:431-444.
26. Tseng CH, Huang YK, Huang YL, Chung CJ, Yang MH, Chen CJ, Hsueh YM: Arsenic exposure, urinary arsenic speciation, and peripheral vascular disease in blackfoot disease-hyperendemic villages in Taiwan. Toxicol Appl Pharmacol 2005;206:299-308.
27. Lee HH, Chao HT, Ng HT, Choo KB: Direct molecular diagnosis of CYP21 mutations in congenital adrenal hyperplasia. J Med Genet 1996;33:371-375.
28. Choi JY, Lee KM, Cho SH, Kim SW, Choi HY, Lee SY, Im HJ, Yoon KJ, Choi H, Choi I, Hirvonen A, Hayes RB, Kang D: CYP2E1 and NQO1 genotypes, smoking and bladder cancer. Pharmacogenetics 2003;13:349-355.
29. Goodman AI, Choudhury M, da Silva JL, Schwartzman ML, Abraham NG: Overexpression of the heme oxygenase gene in renal cell carcinoma. Proc Soc Exp Biol Med 1997;214:54-61.
30. Fang J, Sawa T, Akaike T, Akuta T, Sahoo SK, Khaled G, Hamada A, Maeda H: In vivo antitumor activity of pegylated zinc protoporphyrin: targeted inhibition of heme oxygenase in solid tumor. Cancer Res 2003;63:3567-3574.
31. Malaguarnera L, Quan S, Pilastro MR, Abraham NG, Kappas A: Diminished heme oxygenase potentiates cell death: pyrrolidinedithiocarbamate mediates oxidative stress. Exp Biol Med (Maywood) 2003;228:459-465.
32. Kaneda H, Ohno M, Taguchi J, Togo M, Hashimoto H, Ogasawara K, Aizawa T, Ishizaka N, Nagai R: Heme oxygenase-1 gene promoter polymorphism is associated with coronary artery disease in Japanese patients with coronary risk factors. Arterioscler Thromb Vasc Biol 2002;22:1680-1685.
33. Chang KW, Lee TC, Yeh WI, Chung MY, Liu CJ, Chi LY, Lin SC: Polymorphism in heme oxygenase-1 (HO-1) promoter is related to the risk of oral squamous cell carcinoma occurring on male areca chewers. Br J Cancer 2004;91:1551-1555.
34. Syrigos KN, Harrington KJ, Karayiannakis AJ, Sekara E, Chatziyianni E, Syrigou EI, Waxman J: Clinical significance of heat shock protein-70 expression in bladder cancer. Urology 2003;61:677-680.
35. Moore LE, Smith AH, Eng C, DeVries S, Kalman D, Bhargava V, Chew K, Ferreccio C, Rey OA, Hopenhayn C, Biggs ML, Bates MN, Waldman FM: P53 alterations in bladder tumors from arsenic and tobacco exposed patients. Carcinogenesis 2003;24:1785-1791.
36. Marsit CJ, Karagas MR, Danaee H, Liu M, Andrew A, Schned A, Nelson HH, Kelsey KT: Carcinogen exposure and gene promoter hypermethylation in bladder cancer. Carcinogenesis 2006;27:112-116.
37. Moore LE, Smith AH, Eng C, Kalman D, DeVries S, Bhargava V, Chew K, Moore D, Ferreccio C, Rey OA, Waldman FM: Arsenic-related chromosomal alterations in bladder cancer. J Natl Cancer Inst 2002;94:1688-1696.
38. Kitchin KT: Recent advances in arsenic carcinogenesis: modes of action, animal model systems, and methylated arsenic metabolites. Toxicol Appl Pharmacol 2001;172:249-261.
39. Gebel TW: Arsenic methylation is a process of detoxification through accelerated excretion. Int J Hyg Environ Health 2002;205:505-508.
40. Styblo M, Del Razo LM, Vega L, Germolec DR, LeCluyse EL, Hamilton GA, Reed W, Wang C, Cullen WR, Thomas DJ: Comparative toxicity of trivalent and pentavalent inorganic and methylated arsenicals in rat and human cells. Arch Toxicol 2000;74:289-299.
41. Mass MJ, Tennant A, Roop BC, Cullen WR, Styblo M, Thomas DJ, Kligerman AD: Methylated trivalent arsenic species are genotoxic. Chem Res Toxicol 2001;14:355-361.
42. Nesnow S, Roop BC, Lambert G, Kadiiska M, Mason RP, Cullen WR, Mass MJ: DNA damage induced by methylated trivalent arsenicals is mediated by reactive oxygen species. Chem Res Toxicol 2002;15:1627-1634.
43. Lin S, Del Razo LM, Styblo M, Wang C, Cullen WR, Thomas DJ: Arsenicals inhibit thioredoxin reductase in cultured rat hepatocytes. Chem Res Toxicol 2001;14:305-311.
44. Styblo M, Serves SV, Cullen WR, Thomas DJ: Comparative inhibition of yeast glutathione reductase by arsenicals and arsenothiols. Chem Res Toxicol 1997;10:27-33.
45. Steinmaus C, Yuan Y, Kalman D, Atallah R, Smith AH: Intraindividual variability in arsenic methylation in a US population. Cancer Epidemiol Biomarkers Prev 2005;14:919-924.
46. Chung JS, Kalman DA, Moore LE, Kosnett MJ, Arroyo AP, Beeris M, Mazumder DN, Hernandez AL, Smith AH: Family correlations of arsenic methylation patterns in children and parents exposed to high concentrations of arsenic in drinking water. Environ Health Perspect 2002;110:729-733.
47. Vahter M: Mechanisms of arsenic biotransformation. Toxicology 2002;181-182:211-217.
48. Buchet JP, Geubel A, Pauwels S, Mahieu P, Lauwerys R: The influence of liver disease on the methylation of arsenite in humans. Arch Toxicol 1984;55:151-154.
49. Buchet JP, Lauwerys R: Study of factors influencing the in vivo methylation of inorganic arsenic in rats. Toxicol Appl Pharmacol 1987;91:65-74.
50. Georgiou I, Filiadis IF, Alamanos Y, Bouba I, Giannakopoulos X, Lolis D: Glutathione S-transferase null genotypes in transitional cell bladder cancer: a case-control study. Eur Urol 2000;37:660-664.
51. Kim EJ, Jeong P, Quan C, Kim J, Bae SC, Yoon SJ, Kang JW, Lee SC, Jun WJ, Kim WJ: Genotypes of TNF-alpha, VEGF, hOGG1, GSTM1, and GSTT1: useful determinants for clinical outcome of bladder cancer. Urology 2005;65:70-75.